| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66c1b22707b0276e3078713a6ddcba91 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2006-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62cc21588966c3db88b6af30533dbb29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f7e52d13c2bea89aae30e7d6d376061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d690535564405ae5cc6c04701233c14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4e361fa29f88090286a0ead69550e26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a7fa79a22ed271b66ff57443c161fed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fd36cbe6d410a4368d75fa6bca67a3b |
| publicationDate |
2009-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-101365715-A |
| titleOfInvention |
Matrix metalloproteinase 11 vaccine |
| abstract |
Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110418648-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110418648-B |
| priorityDate |
2005-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |